Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2013-09-04

Clinical Trial Update: Panitumumab and Irinotecan for Malignant Gliomas [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating panitumumab in combination with irinotecan for malignant glioma was terminated with results posted in 2013.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Irinotecan (Irinotecan)
  • Panitumumab (panitumumab)

Snippet

Sponsor: Annick Desjardins | Conditions: Malignant Glioma of Brain | Phase 2 | Status: TERMINATED | Results posted: 2013-09-04